“Our hope for patients suffering from TRD is that their serious, but often treatable condition is recognized earlier in the treatment paradigm, and they are put on a treatment that works best for their specific type of depression.”
“Depression is often perceived as one type of illness, but in fact, an estimate of one-third of the 21 million adults living with major depressive disorder (MDD) have treatment-resident depression, or TRD.”
Ten years ago, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to SPRAVATO® (esketamine) CIII nasal spray. Although progress in the treatment of TRD and MDD has been made over the past decade, there is still a need for more mental health innovation.
In this Mental Health Minute, Reina Benabou, MD, PhD, vice president and head of medical affairs at Janssen Neuroscience, discusses advances in treatment since the FDA approval of SPRAVATO for adults with TRD, as well as the current challenges, needs, and opportunities for medical innovation.
Dr Benabou is vice president and head of medical affairs at Janssen Neuroscience.